Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 06, 2021 08:00 ET | Source: IO Biotech

IO Biotech Announces Third Clinical Collaboration with Merck to Evaluate IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Phase 2 Multi-Arm Basket Trial

NEW YORK, Dec. 06, 2021 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology...
November 09, 2021 11:06 ET | Source: IO Biotech

IO Biotech, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

WILMINGTON, Del., Nov. 09, 2021 (GLOBE NEWSWIRE) -- IO Biotech, Inc. (Nasdaq: IOBT) (“IO Biotech”) today announced the closing of its initial public offering of 8,222,500 shares of its common stock,...
November 04, 2021 23:52 ET | Source: IO Biotech

IO Biotech, Inc. Announces Pricing of Initial Public Offering

WILMINGTON, Del., Nov. 04, 2021 (GLOBE NEWSWIRE) -- IO Biotech, Inc. (Nasdaq: IOBT) (“IO Biotech”) today announced the pricing of its initial public offering of 7,150,000 shares of its common stock...